Education Use Only
For educational use only — Not for clinical decision-making without independent verification
Medical Associates  ·  Department of Nephrology ← Maintenance Hemodialysis module  ·  urinenephrology.org
Clinical Mastery Series  ·  Maintenance Hemodialysis

Hyperkalemia on HD: interdialytic control, binders, emergencies

Why the bath is a weak lever for chronic hyperkalemia, what diet, bowel, drugs, binders, and time can do, and how to manage a dangerous potassium
Andrew Bland, MD, FACP, FAAP UICOMP · UDPA · Butler COM Reviewed September 2026 16 min read

Bottom line

Part of the Maintenance Hemodialysis mastery module. Potassium is reported in mEq/L (numerically identical to mmol/L). “2K” means a dialysate potassium of 2 mEq/L; “pre-HD K” means the serum potassium drawn immediately before the session.

  • The bath is a weak lever for chronic hyperkalemia. A 1 mEq/L lower bath changed the next pre-dialysis potassium by about 0.09 mEq/L in DOPPS instrumental-variable analysis 1. Potassium that accumulates over the long interval is a problem of intake, gut excretion, cellular uptake, and delivered treatment.
  • Work up before you lower the bath: missed or shortened treatments, processed-food additives and salt substitutes, constipation, new drugs, hyperglycemia, and whether a prescribed binder is actually taken.
  • Binders normalize potassium; they have not yet been shown to prevent arrhythmic events. In DIALIZE-Outcomes (RCT, 2,690 patients), sodium zirconium cyclosilicate raised normokalemia at 12 months from 47.0% to 74.0% (NNT 4) but left the sudden death, stroke, or arrhythmia composite unchanged (HR 0.98) 2.
  • Spironolactone for cardiovascular protection lost its outcome case in 2025. ACHIEVE (HR 0.92, 0.78–1.09) and ALCHEMIST (HR 1.00, 0.73–1.36) were both neutral 3,4, leaving little benefit to weigh against recurrent hyperkalemia.
  • Emergency: stabilize, shift, then remove. For potassium of 6.5 mEq/L or higher, symptoms, or ECG change, give IV calcium for ECG changes, insulin with dextrose, and albuterol as a bridge, then dialyze 5,6. The terminal rhythm on hemodialysis is usually bradycardia or asystole 7,8; slow is the warning sign.
  • Plan for rebound. About 35% of the intradialytic fall returns within an hour and about 70% by six hours 5. Recheck 4–6 hours after an emergency treatment or the next morning, and never supplement potassium on an immediate post-dialysis value.

1. Chronic interdialytic hyperkalemia

Definition and scale

Chronic interdialytic hyperkalemia means a pre-dialysis serum potassium repeatedly at or above 5.5 mEq/L, most often after the long weekend interval. It is common. National US cohorts logged 16.3–16.8 hyperkalemia episodes per 100 patient-months, 2.0–2.4 times more often after the long interval 9. In one large dialysis organization, about 20% of pre-dialysis values were 5.5 mEq/L or higher and about 12.5% were 6.0 or higher 10.

The key fact for management is that the dialysate is a weak lever. A 1 mEq/L lower bath changed the next pre-dialysis potassium by about 0.09 mEq/L 1. Bath selection itself is covered in Dialysate potassium: bath selection and the rule of 7 vs 8.

The workup: ten questions before touching the bath

  1. Is it real? Repeat a doubtful value; hemolysis is a frequent source of error 11.
  2. Were treatments missed, shortened, or interrupted? Treatment time under 210 minutes was associated with sudden death in DOPPS (HR 1.13) 12.
  3. Is the delivered dose adequate: blood flow, access function, Kt/V?
  4. What is the patient eating, and what kind of potassium (additives and processed foods versus whole plant foods)?
  5. Is the patient constipated?
  6. Is there a new or uptitrated RAAS inhibitor, mineralocorticoid receptor antagonist, beta-blocker, heparin, trimethoprim, or NSAID?
  7. Hyperglycemia or insulin deficiency? Hypertonic hyperglycemia shifts potassium out of cells 5.
  8. Worsening metabolic acidosis?
  9. Tissue breakdown, hemolysis, or gastrointestinal bleeding?
  10. Is a binder already prescribed, and is it taken?

2. Diet: the plant-food evidence has changed

Traditional counseling restricts fruits and vegetables. The evidence for that approach is thin and mixed, and newer cohort data point the other way. All four studies below are observational.

StudyPopulationFinding
Noori 2010 13224 HD patients, food-frequency questionnaireHighest vs lowest potassium-intake quartile: HR 2.4 (1.1–7.5) for death, after adjustment including serum potassium
DIET-HD 2021 148,043 HD patients, Europe and South AmericaPotassium intake not associated with death (HR 1.00 per g/day), with serum potassium (+0.03 mEq/L per g/day), or with hyperkalemia of 6.0 or higher (OR 1.11, 0.89–1.37)
Narasaki 2021 15415 HD patientsLowest intake tertile associated with higher mortality (HR 1.74, 1.14–2.66)
Narasaki 2026 16687 HD patientsHigh-potassium, high-fiber intake associated with lower mortality than low/low (HR 0.69, 0.50–0.96) and better physical-function quality of life

The argument is that potassium sources are not equivalent. Plant and animal sources may differ in how much they raise serum potassium, and potassium-rich plant foods carry fiber, vitamins, and minerals that may account for their benefits 17,18,19. Potassium additives in processed foods have become a separate counseling target 20. A KDIGO Controversies Conference described a shift from dietary restriction toward eating patterns associated with better outcomes, while noting how few data show that diet change restores an abnormal serum potassium 21. A 2016 commentary judged traditional restriction of high-potassium plant foods not evidence-based, yet advised continuing it until trials report 17. That trial is under way: the EvoKe-HD pilot randomizes hyperkalemic patients to targeted counseling (additives and selected high-impact foods) versus standard total-potassium restriction 20.

Practical translation

In a hyperkalemic patient, look first at additive-laden processed foods, salt substitutes (potassium chloride), and large single loads. Do not strip whole fruits and vegetables from an already restricted diet without a reason.

3. Constipation and medications

Constipation

Gut excretion is a major potassium exit in anuric patients, fecal potassium output tracks stool volume, and constipation affects about 40% of hemodialysis patients 5. In 36,116 US veterans in the year before dialysis (observational), laxative use was associated with 21% lower odds of hyperkalemia (adjusted OR 0.79, 0.76–0.84) without more hypokalemia 22. That is a pre-dialysis population and an observational signal, but a bowel regimen is cheap, and constipation belongs in every hyperkalemia review.

RAAS inhibitors and mineralocorticoid receptor antagonists

In oligoanuric hemodialysis patients, stopping an ACE inhibitor or spironolactone lowered serum potassium by about 0.2–0.6 mEq/L, attributed to effects on colonic secretion 10. The case for continuing a mineralocorticoid receptor antagonist for cardiovascular protection weakened substantially in 2025:

Trial (design)PatientsPrimary outcomeResult
ACHIEVE (RCT) 42,538 on maintenance dialysis, after open-label run-inCV death or heart-failure hospitalization10.46 vs 11.33 events per 100 patient-years; HR 0.92 (0.78–1.09); stopped for futility. Absolute difference 0.87 per 100 patient-years, not significant
ALCHEMIST (RCT) 3644 high-CV-risk HD patients, after run-inMajor adverse cardiovascular events24% vs 24%; HR 1.00 (0.73–1.36); stopped early for lack of funding. Potassium above 6.0 in 42% vs 41%

Both trials enrolled only patients who tolerated a run-in, so the similar hyperkalemia rates in ALCHEMIST do not show that spironolactone is potassium-neutral in unselected patients 3. When a dialysis patient has recurrent hyperkalemia on spironolactone prescribed for cardiovascular protection rather than a specific heart-failure indication, the 2025 trials leave little outcome benefit to weigh against it 3,4. Heart-failure-specific decisions belong with cardiology.

4. Potassium binders on hemodialysis

Agent and studyDesignKey numbersARR / NNT and cautions
Sodium zirconium cyclosilicate (SZC) — DIALIZE 23RCT, 196 patients, 4-week evaluation; 5 g once daily on non-dialysis days, titrated in 5-g steps to 15 gResponders (pre-HD K 4.0–5.0 on at least 3 of 4 long-interval visits, no rescue): 41.2% vs 1.0%Absolute increase 40.2 points; NNT 3 over 4 weeks (surrogate endpoint). Manufacturer-sponsored; serious adverse events 7% vs 8%
SZC — DIALIZE-Outcomes 2RCT, 2,690 patients with pre-HD K of 5.5 or higher; terminated early at about 33% of planned events with high drug discontinuationSudden death, stroke, or arrhythmia composite 8.8% vs 8.9%, HR 0.98 (0.76–1.26). Normokalemia at 12 months 74.0% vs 47.0% (OR 3.36)Composite: no difference. Normokalemia: ARR 27.0 points, NNT 4. Hypokalemia 3.0% vs 1.4% (NNH about 63). No volume signal: edema 5% vs 5% 24
SZC — Jiang 2026 25Open-label single-center RCT, 116 patients, 6 monthsPre-HD K after the long interval −0.36 mEq/L (−0.54 to −0.18) vs control; mild hypokalemia 8.6%, constipation 6.9%Surrogate endpoint; retrospectively registered
Patiromer 26,27Observational only in HD; no HD outcome RCT identified527 initiators: mean K fell about 0.5 mEq/L; K of 6.0 or higher in 48% before vs 22% after. 10,860 initiators (single arm): K below 5.5 in 35.6% → 69.9%; 1K bath use 17.2% → 11.0%; hyperkalemia hospitalizations 0.35 → 0.20 per person-yearNot derivable (no control group). 8.4 g once daily was the usual dose; a single-arm design cannot establish causation
Sodium polystyrene sulfonate (SPS) 28,29No HD randomized evidence identifiedSystematic review: 58 cases of GI injury, colon in 76%, transmural necrosis in 62%, 33% mortality. Older adults (not dialysis-specific): serious GI events HR 1.94 (1.10–3.41) within 30 daysAbsolute GI harm about 0.1% at 30 days (NNH about 1,000 in that population). Slow, unpredictable onset 5

The ADAPT crossover trial tested a binder differently: 3K dialysate plus SZC on non-dialysis days against 2K with no binder, and found fewer device-detected AF episodes and arrhythmias with the combination 30. The design and its limits are covered in the bath selection page.

Clinical Pearl — binders lower potassium; they have not yet been shown to prevent arrhythmic events

DIALIZE-Outcomes, the only large outcome trial, improved normokalemia by 27 percentage points and changed the arrhythmic composite by nothing measurable 2. Its early termination leaves the question open rather than closed. The strongest current use of a binder is the one ADAPT tested: allowing a higher, gentler bath without paying for it in pre-dialysis hyperkalemia 30.

5. Treatment time, frequency, and where the low bath fits

If the potassium load exceeds what three sessions can remove, add time or add a session before dropping to 1K. The UK Renal Association lists increased dialysis frequency among first-line measures 11, and a published algorithm lengthens treatment time before lowering the bath to 1K 10. Short treatment time was associated with sudden death in DOPPS 12. Extra time also addresses the volume problem that usually travels with the potassium problem (see Ultrafiltration rate and treatment time).

The low bath comes last, and temporarily. Guidance converges on a combined approach—diet, medication review, binders, frequency—with the bath lowered only when those are not possible or not enough, and then no lower than necessary 11. When 1K is used, check potassium at least weekly 10.

6. Severe and emergent hyperkalemia on hemodialysis

Thresholds and first moves

Severe hyperkalemia, for chair-side purposes, means a pre-dialysis potassium of 6.5 mEq/L or higher, or any potassium with symptoms (weakness, paralysis, palpitations, syncope) or ECG changes (peaked T waves, widened QRS, bradycardia, heart block). The terminal rhythm in dialysis patients is usually bradycardia or asystole 7,8.

StepDetail
Confirm without delayingRepeat a doubtful, hemolyzed sample, but do not delay treatment when the ECG is abnormal 11
Stabilize the membraneIV calcium (1 g calcium chloride or calcium gluconate over 2–3 minutes) when ECG changes are present; repeat if changes persist or recur; it does not lower potassium 6
Shift potassium into cellsInsulin 10 units IV with 25–40 g dextrose lowers potassium about 1 mEq/L, onset under 20 minutes, peak at 30–60 minutes; follow with dextrose infusion to prevent hypoglycemia 5,31. Nebulized albuterol 10–20 mg lowers potassium about 0.6–1.0 mEq/L and is additive with insulin (combined about 1.2 mEq/L) 5; up to 40% of patients with kidney failure are resistant to albuterol 6
BicarbonateIV bicarbonate over 60 minutes did not lower potassium in maintenance HD patients 31; it may help in marked metabolic acidosis 6
Remove potassiumHemodialysis is the fastest route: 5.63 → 4.29 mEq/L in one hour, versus 5.62 → 4.70 with a 60-minute insulin–glucose infusion, in a within-patient comparison of 10 maintenance patients 31

A trade-off hides in this sequence. Insulin and albuterol given before dialysis reduce the amount of potassium dialysis can then remove and may exaggerate the rebound 5. They remain correct when the ECG is abnormal or dialysis is delayed, but they are a bridge, and the post-dialysis plan must assume more rebound.

When a low bath is justified

The strongest case for 1K, occasionally 0K, is severe hyperkalemia in a patient who needs the potassium out now. One review argues that the sudden-death associations for low baths come from patients with normal or near-normal potassium, that low baths in genuinely hyperkalemic patients were associated with less sudden death and mortality in two cohorts 6,32,33, and recommends 0K for potassium of 7 mEq/L or higher during a 3-hour treatment 6. In the 14 Blumberg patients dialyzed against 1K, no patient’s post-rebound potassium ended comfortably in the normal range 6. Against this sit a higher mortality signal with 1K at potassium of 5 or more 34 and the in-unit arrest associations 35,36.

Reasonable synthesis: for potassium of 6.5 mEq/L or higher or ECG changes, a 1K bath (0K only for extreme values) with continuous cardiac monitoring for the whole treatment 5, an intradialytic potassium check when feasible, and a return to the usual bath at the next session. Where available, a stepped bath (2K for the first hour, then lower) blunts the early gradient 37,38.

During the treatment

  • Monitor rhythm continuously when a 0K or 1K bath is used for hyperkalemia 5.
  • Expect the steepest fall in the first hour and a plateau after about 3 hours 5,39. Extending a treatment past the plateau removes relatively little additional potassium; a second session later is often more effective.
  • High dialysate bicarbonate accelerates the serum fall without increasing removal 40; the monitor may look better than the potassium balance is.

Rebound and post-dialysis checks

About 35% of the intradialytic fall returns within one hour and about 70% by six hours 5; in the Blumberg series, 3.62 mEq/L at the end of treatment became 5.01 six hours later 39. The post-rebound value tracks the starting value 39. For a pre-dialysis potassium of 7 or higher, after an emergency treatment on a low bath, or after pre-dialysis insulin or albuterol, plan a potassium check 4–6 hours after dialysis or the next morning, and a repeat treatment sooner than the regular schedule if needed 5,39. The 4–6-hour window is a practice point derived from the rebound kinetics, not a tested protocol.

Do not supplement potassium immediately after dialysis

The end-of-treatment value is the nadir of a curve that is already rising 5,39. Post-dialysis hypokalemia was associated with mortality only until pre-dialysis potassium was accounted for 41, so the post-dialysis number is not an independent treatment target. For a chronically low potassium, raise the bath rather than giving potassium after the session. If supplementation is truly needed, base it on a value drawn after the rebound window or on the next pre-dialysis value.

After the emergency

Reset the bath at the next treatment. Find the cause with the ten-question workup. Document the event and the plan so the next shift does not inherit a 0K or 1K order meant for one session 10,35.

7. Interactions with the rest of the dialysate and the drug list

The potassium bath does not act alone. Full coverage of calcium, bicarbonate, magnesium, and glucose is in Dialysate calcium, bicarbonate, magnesium, and glucose and of sodium in Dialysate sodium; this section covers only what changes potassium decisions.

ComponentWhat the evidence showsPractical reading
BicarbonateHigher dialysate bicarbonate (39 vs 35 vs 27 mEq/L) produced a faster, deeper potassium fall by shift, with no increase in removal 40. Dialysate bicarbonate of 38 or higher was used in 45% of US DOPPS patients, and mortality rose 8% per 4 mEq/L (HR 1.08, 1.01–1.15) 42. In MiD, bicarbonate above 35 was associated with more AF (IRR 3.18, 1.13–8.94) 43, while its association with fewer arrhythmias lost significance after adjustment for potassium 44Avoid dialysate bicarbonate above 35 mEq/L in hypokalemia-prone patients 10
CalciumIn 510 witnessed arrests, dialysate calcium below 2.5 mEq/L was associated with in-unit arrest (OR 2.00, 1.40–2.90), as was a larger serum-to-dialysate calcium gradient (OR 1.40) 45; low-calcium dialysate was also associated with arrest in an earlier case-control study 36. In the MiD loop-recorder cohort, dialysate calcium above 2.5 was associated with less AF (IRR 0.62, 0.48–0.80) 43. Lower ionized calcium was associated with longer QTc 46ADAPT used 2.5 mEq/L calcium in both arms 30. Avoid pairing a low potassium bath with a low calcium bath
MagnesiumDialysate magnesium may interact with potassium-related risk 47. Hypomagnesemia is associated with cardiovascular events and mortality in hemodialysis, and a Canadian cluster-randomized trial of 0.75 versus 0.50 mmol/L or less has not yet reported 48. Serum magnesium was not associated with QTc in one cohort 46Avoid dialysate magnesium below 1 mEq/L in hypokalemia-prone patients 10; evidence for magnesium as an arrhythmia lever remains mostly surrogate
Glucose and sodiumGlucose-free dialysate increases potassium removal (about 28% more in one study) through lower insulin 5,49. Very high dialysate glucose with abrupt correction of profound acidosis can drive post-dialysis potassium below the bath 5. A dialysate sodium of 143 versus 138 mEq/L exaggerated post-dialysis rebound 5Dialysate glucose and sodium choices are made on their own evidence (see the linked composition pages), but expect them to shift potassium
DigoxinMortality HR 1.28 overall; per-ng/mL risk concentrated where pre-dialysis potassium was below 4.3 (HR 2.53) 50. Digoxin plus left ventricular hypertrophy predicted dialysis-related ventricular arrhythmias, and a higher bath reduced ectopy 51Avoid sub-2 baths in digoxin-treated patients; favor 3K
QT-prolonging drugsAmiodarone was associated with sudden death in DOPPS 12; signals for other agents are mixed 45,52; lower potassium lengthens QTc 46Do not combine QT-prolonging drugs with low potassium or low calcium baths when an alternative exists

Evidence gaps

  • No randomized trial of bath potassium on hard outcomes; ADAPT changed bath and binder together and measured device-detected rhythm 30.
  • Hyperkalemic patients on 1K: the literature points in both directions, with very few patients above 6 mEq/L in any cohort 32,33,34.
  • Post-dialysis potassium is rarely measured, and its independent prognostic value is doubtful once pre-dialysis potassium is known 41.
  • Binders normalize potassium but have not reduced arrhythmic outcomes in the one large trial, which terminated early 2; patiromer has no hemodialysis outcome trial identified 26,27.
  • Diet: whether targeted counseling (additives, processed foods) beats total-potassium restriction is only now being tested 20.
  • Magnesium as an arrhythmia lever awaits the Canadian cluster trial 48.
  • Rebound timing: the 4–6-hour post-dialysis recheck is derived from kinetics, not tested as a protocol 5,39.

At the chair

For dialysis nurses and technicians

Report a pre-dialysis potassium of 6.5 mEq/L or higher, weakness, palpitations, or any ECG change before starting; slow heart rates are the warning sign. When a 0K or 1K bath is ordered for hyperkalemia, keep the patient on a cardiac monitor for the whole treatment. Ask about missed sessions, constipation, new medications, and salt substitutes; these findings change the plan more than the bath does. Never give potassium on an end-of-treatment value, and make sure a one-session low-bath order is not carried forward.

Nursing card N1: Potassium bath selection — do this, call when, don’t, and why

The physician’s written order and the unit protocol always govern.

Also in this module

References

References are carried from a reference-checked evidence review (September 2026) and renumbered for this page. Each was checked against its PubMed record, full text, or the issuing agency’s document.

  1. Karaboyas A, Zee J, Brunelli SM, et al. Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2017;69(2):266-277. PMID: 27866964
  2. Fishbane S, Dember LM, Jadoul M, et al. The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis. Kidney Int. 2025;108(4):686-694. PMID: 40618849
  3. Rossignol P, Zannad F, Massy Z, et al; ALCHEMIST study group. Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet. 2025;406(10504):705-718. PMID: 40818851
  4. Walsh M, Collister D, Gallagher M, et al; ACHIEVE Investigators. Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial. Lancet. 2025;406(10504):695-704. PMID: 40818850
  5. Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial. 2001;14(5):348-356. PMID: 11679104
  6. Abuelo JG. Treatment of severe hyperkalemia: confronting 4 fallacies. Kidney Int Rep. 2018;3(1):47-55. PMID: 29340313
  7. Roy-Chaudhury P, Tumlin JA, Koplan BA, et al. Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. Kidney Int. 2018;93(4):941-951. PMID: 29395340
  8. Wong MC, Kalman JM, Pedagogos E, et al. Temporal distribution of arrhythmic events in chronic kidney disease: highest incidence in the long interdialytic period. Heart Rhythm. 2015;12(10):2047-2055. PMID: 26111801
  9. Yusuf AA, Hu Y, Singh B, Menoyo JA, Wetmore JB. Serum potassium levels and mortality in hemodialysis patients: a retrospective cohort study. Am J Nephrol. 2016;44(3):179-186. PMID: 27592170
  10. Pun PH. Dialysate potassium concentration: should mass balance trump electrophysiology? Semin Dial. 2018;31(6):569-575. PMID: 30027592
  11. Ashby D, Borman N, Burton J, et al. Renal Association clinical practice guideline on haemodialysis. BMC Nephrol. 2019;20(1):379. PMID: 31623578
  12. Jadoul M, Thumma J, Fuller DS, et al. Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol. 2012;7(5):765-774. PMID: 22403271
  13. Noori N, Kalantar-Zadeh K, Kovesdy CP, et al. Dietary potassium intake and mortality in long-term hemodialysis patients. Am J Kidney Dis. 2010;56(2):338-347. PMID: 20580474
  14. Bernier-Jean A, Wong G, Saglimbene V, et al. Dietary potassium intake and all-cause mortality in adults treated with hemodialysis. Clin J Am Soc Nephrol. 2021;16(12):1851-1861. PMID: 34853064
  15. Narasaki Y, Okuda Y, Kalantar SS, et al. Dietary potassium intake and mortality in a prospective hemodialysis cohort. J Ren Nutr. 2021;31(4):411-420. PMID: 33121888
  16. Narasaki Y, Li Z, Ong M, et al. Dietary potassium and fiber intake, survival, and health-related quality of life, in a prospective multi-center hemodialysis cohort. Clin Nutr. 2026;59:106599. PMID: 41747650
  17. St-Jules DE, Goldfarb DS, Sevick MA. Nutrient non-equivalence: does restricting high-potassium plant foods help to prevent hyperkalemia in hemodialysis patients? J Ren Nutr. 2016;26(5):282-287. PMID: 26975777
  18. Clegg DJ, Headley SA, Germain MJ. Impact of dietary potassium restrictions in CKD on clinical outcomes: benefits of a plant-based diet. Kidney Med. 2020;2(4):476-487. PMID: 32775988
  19. Sumida K, Biruete A, Kistler BM, et al. New insights into dietary approaches to potassium management in chronic kidney disease. J Ren Nutr. 2023;33(6S):S6-S12. PMID: 37610407
  20. Bernier-Jean A, Goupil R, Madore F, et al. A pilot randomised controlled trial of a targeted dietary approach to potassium management in hemodialysis: a clinical research protocol for the EvoKe-HD study. Can J Kidney Health Dis. 2026;13:20543581261476635. PMID: 42625998
  21. Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a KDIGO Controversies Conference. Kidney Int. 2020;97(1):42-61. PMID: 31706619
  22. Sumida K, Dashputre AA, Potukuchi PK, et al. Laxative use and risk of dyskalemia in patients with advanced CKD transitioning to dialysis. J Am Soc Nephrol. 2021;32(4):950-959. PMID: 33547216
  23. Fishbane S, Ford M, Fukagawa M, et al. A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia. J Am Soc Nephrol. 2019;30(9):1723-1733. PMID: 31201218
  24. Fishbane S, Dember LM, Jadoul M, et al. Effects of sodium zirconium cyclosilicate on volume status in maintenance hemodialysis: post hoc analysis from the DIALIZE-Outcomes trial. Kidney360. 2026 (online ahead of print). PMID: 42560771
  25. Jiang Y, Fang Y, Gong F, et al. Efficacy and safety of sodium zirconium cyclosilicate on non-dialysis days for long-term management of chronic hyperkalemia in maintenance hemodialysis: a single-center, prospective, open-label, randomized controlled trial. Int Urol Nephrol. 2026 (online ahead of print). PMID: 42474674
  26. Kovesdy CP, Rowan CG, Conrad A, et al. Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients. Kidney Int Rep. 2019;4(2):301-309. PMID: 30775627
  27. Zhou M, Ruessmann D, Ficociello LH, et al. Real-world effectiveness of patiromer among hemodialysis patients: a one-year retrospective cohort study. BMC Nephrol. 2026;27(1). PMID: 42363136
  28. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126(3):264.e9-24. PMID: 23321430
  29. Noel JA, Bota SE, Petrcich W, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med. 2019;179(8):1025-1033. PMID: 31180477
  30. Charytan DM, Winkelmayer WC, Granger CB, et al; ADAPT Investigators. Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia. Kidney Int. 2025;107(1):169-179. PMID: 39490411
  31. Blumberg A, Weidmann P, Shaw S, Gnädinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med. 1988;85(4):507-512. PMID: 3052050
  32. Kovesdy CP, Regidor DL, Mehrotra R, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol. 2007;2(5):999-1007. PMID: 17702709
  33. Huang CW, Lee MJ, Lee PT, et al. Low potassium dialysate as a protective factor of sudden cardiac death in hemodialysis patients with hyperkalemia. PLoS One. 2015;10(10):e0139886. PMID: 26440515
  34. Ferrey A, You AS, Kovesdy CP, et al. Dialysate potassium and mortality in a prospective hemodialysis cohort. Am J Nephrol. 2018;47(6):415-423. PMID: 29879714
  35. Karnik JA, Young BS, Lew NL, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60(1):350-357. PMID: 11422771
  36. Pun PH, Lehrich RW, Honeycutt EF, Herzog CA, Middleton JP. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int. 2011;79(2):218-227. PMID: 20811332
  37. Chandra A, Rao N, Kulshreshtha MR. Controlled potassium reduction using dialysate profiling in hyperkalemic hemodialysis patients: a randomized study. Int J Artif Organs. 2025;48(11):813-818. PMID: 41185428
  38. Redaelli B, Locatelli F, Limido D, et al. Effect of a new model of hemodialysis potassium removal on the control of ventricular arrhythmias. Kidney Int. 1996;50(2):609-617. PMID: 8840293
  39. Blumberg A, Roser HW, Zehnder C, Müller-Brand J. Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium. Nephrol Dial Transplant. 1997;12(8):1629-1634. PMID: 9269640
  40. Heguilén RM, Sciurano C, Bellusci AD, et al. The faster potassium-lowering effect of high dialysate bicarbonate concentrations in chronic haemodialysis patients. Nephrol Dial Transplant. 2005;20(3):591-597. PMID: 15687112
  41. Ohnishi T, Kimachi M, Fukuma S, Akizawa T, Fukuhara S. Postdialysis hypokalemia and all-cause mortality in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. 2019;14(6):873-881. PMID: 31048327
  42. Tentori F, Karaboyas A, Robinson BM, et al. Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2013;62(4):738-746. PMID: 23707043
  43. Koplan BA, Winkelmayer WC, Costea AI, et al. Implantable loop recorder monitoring and the incidence of previously unrecognized atrial fibrillation in patients on hemodialysis. Kidney Int Rep. 2022;7(2):189-199. PMID: 35155858
  44. Ravi KS, Tumlin JA, Roy-Chaudhury P, et al; MiD Investigators. Association of dialysate bicarbonate with arrhythmia in the Monitoring in Dialysis Study. Kidney360. 2024;5(10):1490-1499. PMID: 39480910
  45. Pun PH, Horton JR, Middleton JP. Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8(5):797-803. PMID: 23371957
  46. Kim ED, Watt J, Tereshchenko LG, et al. Associations of serum and dialysate electrolytes with QT interval and prolongation in incident hemodialysis: the PACE study. BMC Nephrol. 2019;20(1):133. PMID: 30999887
  47. Pun PH, Middleton JP. Dialysate potassium, dialysate magnesium, and hemodialysis risk. J Am Soc Nephrol. 2017;28(12):3441-3451. PMID: 28993507
  48. Tannar B, Al-Hellawi H, Sontrop JM, et al; Dial-Mag Investigator Writing Committee. Effects of increasing the concentration of dialysate magnesium on cardiovascular health: a narrative review. Can J Kidney Health Dis. 2026;13:20543581261454463. PMID: 42293164
  49. Sherman RA, Hwang ER, Bernholc AS, Eisinger RP. Variability in potassium removal by hemodialysis. Am J Nephrol. 1986;6(4):284-288. PMID: 3777037
  50. Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010;21(9):1550-1559. PMID: 20576808
  51. Morrison G, Michelson EL, Brown S, Morganroth J. Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients. Kidney Int. 1980;17(6):811-819. PMID: 6447822
  52. Liabeuf S, Berdougo-Tritz J, Augey L, et al. QT-prolonging medications: prevalence of use and associated risks in CKD. Nephrol Dial Transplant. 2026;41(4):614-624. PMID: 40996451